These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 31965135)

  • 21. Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Baran N; Konopleva M
    Clin Cancer Res; 2017 May; 23(10):2382-2390. PubMed ID: 28137923
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent Advances in Nanoplatform Construction Strategy for Alleviating Tumor Hypoxia.
    Shen J; Chen G; Zhao L; Huang G; Liu H; Liu B; Miao Y; Li Y
    Adv Healthc Mater; 2023 Aug; 12(21):e2300089. PubMed ID: 37055912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Engineering Oxygen-Irrelevant Radical Nanogenerator for Hypoxia-Independent Magnetothermodynamic Tumor Nanotherapy.
    Shen Y; Dong C; Xiang H; Li C; Zhuang F; Chen Y; Lu Q; Chen Y; Huang B
    Small Methods; 2021 Apr; 5(4):e2001087. PubMed ID: 34927851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving cancer therapy through the nanomaterials-assisted alleviation of hypoxia.
    Sahu A; Kwon I; Tae G
    Biomaterials; 2020 Jan; 228():119578. PubMed ID: 31678843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulating tumor hypoxia by nanomedicine for effective cancer therapy.
    Jahanban-Esfahlan R; de la Guardia M; Ahmadi D; Yousefi B
    J Cell Physiol; 2018 Mar; 233(3):2019-2031. PubMed ID: 28198007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypoxia: targeting the tumour.
    Boyle RG; Travers S
    Anticancer Agents Med Chem; 2006 Jul; 6(4):281-6. PubMed ID: 16842231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of the tumor vasculature and oxygenation to improve therapy.
    Siemann DW; Horsman MR
    Pharmacol Ther; 2015 Sep; 153():107-24. PubMed ID: 26073310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z; Deng Z; Zhu G
    Dalton Trans; 2019 Feb; 48(8):2536-2544. PubMed ID: 30633263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT).
    Dang J; He H; Chen D; Yin L
    Biomater Sci; 2017 Jul; 5(8):1500-1511. PubMed ID: 28681887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent Advances In Developing Novel Anti-Cancer Drugs Targeting Tumor Hypoxic and Acidic Microenvironments.
    Li W; Sun X
    Recent Pat Anticancer Drug Discov; 2018; 13(4):455-468. PubMed ID: 30173649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506.
    van der Wiel AMA; Jackson-Patel V; Niemans R; Yaromina A; Liu E; Marcus D; Mowday AM; Lieuwes NG; Biemans R; Lin X; Fu Z; Kumara S; Jochems A; Ashoorzadeh A; Anderson RF; Hicks KO; Bull MR; Abbattista MR; Guise CP; Deschoemaeker S; Thiolloy S; Heyerick A; Solivio MJ; Balbo S; Smaill JB; Theys J; Dubois LJ; Patterson AV; Lambin P
    Mol Cancer Ther; 2021 Dec; 20(12):2372-2383. PubMed ID: 34625504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications.
    Ji T; Zhao Y; Ding Y; Nie G
    Adv Mater; 2013 Jul; 25(26):3508-25. PubMed ID: 23703805
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-active nanoparticles used in tumor theranostic.
    Wang Y; Shang W; Niu M; Tian J; Xu K
    Int J Nanomedicine; 2019; 14():3705-3722. PubMed ID: 31190820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the hypoxic microenvironment in the antitumor activity of tyrosine kinase inhibitors.
    Filippi I; Naldini A; Carraro F
    Curr Med Chem; 2011; 18(19):2885-92. PubMed ID: 21651491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia Responsive Drug Delivery Systems in Tumor Therapy.
    Alimoradi H; Matikonda SS; Gamble AB; Giles GI; Greish K
    Curr Pharm Des; 2016; 22(19):2808-20. PubMed ID: 26898739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 - 2021.
    Anduran E; Dubois LJ; Lambin P; Winum JY
    Expert Opin Ther Pat; 2022 Jan; 32(1):1-12. PubMed ID: 34241566
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.
    Benito J; Shi Y; Szymanska B; Carol H; Boehm I; Lu H; Konoplev S; Fang W; Zweidler-McKay PA; Campana D; Borthakur G; Bueso-Ramos C; Shpall E; Thomas DA; Jordan CT; Kantarjian H; Wilson WR; Lock R; Andreeff M; Konopleva M
    PLoS One; 2011; 6(8):e23108. PubMed ID: 21853076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An intelligent dual stimuli-responsive photosensitizer delivery system with O
    Zhao H; Li L; Zheng C; Hao Y; Niu M; Hu Y; Chang J; Zhang Z; Wang L
    Colloids Surf B Biointerfaces; 2018 Jul; 167():299-309. PubMed ID: 29679806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.